Heart failure & cardiomyopathies
Uric Acid is a Biomarker for Heart Failure, but Not Therapeutic Target: Result from a Comprehensive Meta-Analysis
Authors' conclusion
Uric acid is an independent predictor of heart failure occurrence and adverse prognosis. Targeting uric acid lowering as a therapeutic intervention does not improve the prognosis of patients with heart failure.
Study context
- Population
- General population (heart failure (HF) incidence) and patients with HF (adverse outcomes, uric acid-lowering treatment)11 HF-incidence + 24 outcome studies
- Comparison
- Higher vs lower serum uric acid (SUA); uric acid-lowering treatment in HF
- Outcome
- HF incidence and adverse outcomes in HF patients
Methodological detailsrandom or fixed effects models, univariable meta-regression, PubMed and Embase searched
- Random or fixed effects models
- Univariable meta-regression
- PubMed and Embase searched
Pooled result
As reported in the abstract
Higher SUA and risk
Higher SUA vs Lower SUARelative risk (95% CI)
HF incidence
1.81(1.53–2.16)
All-cause mortality in HF
1.44(1.25–1.66)
Cardiac death in HF
1.56(1.32–1.84)
HF rehospitalization
2.07(1.37–3.13)
Further pooled results
All-cause mortality with uric acid-lowering treatment in HF
| RR (95% CI) | ||
|---|---|---|
| Uric acid-lowering treatmentIncreased mortality | 1.15 (1.05–1.25) | |
| 0.512Relative risk (log scale) |
Original publication
Uric Acid is a Biomarker for Heart Failure, but Not Therapeutic Target: Result from a Comprehensive Meta-Analysis. ESC Heart Fail. Published 10 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →